Achieve Life Sciences (ACHV) Competitors $2.55 0.00 (0.00%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.52 -0.03 (-1.18%) As of 08/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACHV vs. VSTM, EBS, XOMA, VNDA, CBIO, CDXS, AGEN, SGMO, IRWD, and DOMHShould you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Verastem (VSTM), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Crescent Biopharma (CBIO), Codexis (CDXS), Agenus (AGEN), Sangamo Therapeutics (SGMO), Ironwood Pharmaceuticals (IRWD), and Dominari (DOMH). These companies are all part of the "biotechnology" industry. Achieve Life Sciences vs. Its Competitors Verastem Emergent Biosolutions XOMA Royalty Vanda Pharmaceuticals Crescent Biopharma Codexis Agenus Sangamo Therapeutics Ironwood Pharmaceuticals Dominari Achieve Life Sciences (NASDAQ:ACHV) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation. Which has more volatility and risk, ACHV or VSTM? Achieve Life Sciences has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Does the media refer more to ACHV or VSTM? In the previous week, Verastem had 10 more articles in the media than Achieve Life Sciences. MarketBeat recorded 12 mentions for Verastem and 2 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.85 beat Verastem's score of 0.48 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of ACHV or VSTM? 33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 3.0% of Achieve Life Sciences shares are owned by insiders. Comparatively, 2.1% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, ACHV or VSTM? Achieve Life Sciences has higher earnings, but lower revenue than Verastem. Verastem is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$39.83M-$1.46-1.75Verastem$10K50,585.88-$130.64M-$3.28-2.51 Is ACHV or VSTM more profitable? Achieve Life Sciences' return on equity of -193.49% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -193.49% -116.68% Verastem N/A -2,003.62%-119.85% Do analysts prefer ACHV or VSTM? Achieve Life Sciences presently has a consensus target price of $16.00, suggesting a potential upside of 527.45%. Verastem has a consensus target price of $13.29, suggesting a potential upside of 61.63%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Achieve Life Sciences is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Verastem 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 SummaryAchieve Life Sciences beats Verastem on 11 of the 15 factors compared between the two stocks. Get Achieve Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHV vs. The Competition Export to ExcelMetricAchieve Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.32M$2.75B$5.66B$9.82BDividend YieldN/A1.77%3.79%4.07%P/E Ratio-1.7521.8930.5825.12Price / SalesN/A735.49464.66115.60Price / CashN/A177.1637.4059.05Price / Book3.115.079.096.18Net Income-$39.83M$31.61M$3.25B$264.89M7 Day Performance2.00%25.12%7.32%4.18%1 Month Performance-5.20%3.84%5.42%1.99%1 Year Performance-43.33%10.43%30.66%24.22% Achieve Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHVAchieve Life Sciences2.2077 of 5 stars$2.55flat$16.00+527.5%-42.7%$130.32MN/A-1.7520VSTMVerastem3.1092 of 5 stars$6.01-1.2%$13.38+122.5%+252.8%$334.09M$10K-1.8850Analyst UpgradeGap DownEBSEmergent Biosolutions4.7132 of 5 stars$5.97+6.0%$14.33+140.3%+2.2%$305.58M$1.04B-2.202,420News CoverageXOMAXOMA Royalty4.4129 of 5 stars$27.25+10.0%$69.50+155.0%+12.8%$296.42M$28.49M-23.7010News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionGap UpVNDAVanda Pharmaceuticals4.4688 of 5 stars$4.26+1.7%$16.50+287.3%-15.7%$247.58M$198.77M-3.77290News CoverageAnalyst RevisionCBIOCrescent Biopharma3.8373 of 5 stars$11.84-1.3%$25.67+116.8%N/A$234.60M$10K-0.3450News CoverageAnalyst RevisionCDXSCodexis3.6615 of 5 stars$2.84+5.6%$11.00+287.3%+7.1%$222.85M$59.35M-2.87250News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionAGENAgenus4.0075 of 5 stars$5.40+0.7%$16.33+202.5%-10.4%$146.95M$103.46M-0.62440News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionSGMOSangamo Therapeutics3.0965 of 5 stars$0.54-4.7%$4.50+741.1%-34.8%$130.95M$57.80M-1.37480News CoveragePositive NewsAnalyst UpgradeShort Interest ↓Analyst RevisionGap UpIRWDIronwood Pharmaceuticals4.4039 of 5 stars$0.75-2.7%$4.78+537.4%-76.9%$124.83M$351.41M-3.75220DOMHDominari0.5637 of 5 stars$5.02+11.6%N/A+278.7%$65.90M$18.15M-1.124News CoverageEarnings ReportAnalyst Upgrade Related Companies and Tools Related Companies VSTM Alternatives EBS Alternatives XOMA Alternatives VNDA Alternatives CBIO Alternatives CDXS Alternatives AGEN Alternatives SGMO Alternatives IRWD Alternatives DOMH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACHV) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access